Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Mease

Showing results (101-110 of 175) with videos related to

Pageof 18
Sort By:
Arthritis and Rheumatism|April 1, 2009
Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled studyArthur Kavanaugh, Iain McInnes, Philip Mease, et al.
Rheumatology and Therapy|April 18, 2024
Exploring the Effects of Ixekizumab on Pain in Patients with Ankylosing Spondylitis Based on Objective Measures of Inflammation: Post Hoc Analysis from a Large Randomized Clinical TrialKurt de Vlam, Walter P Maksymowych, Gaia Gallo, et al.
The Journal of Rheumatology|February 3, 2011
Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for FibromyalgiaFrederick Wolfe, Daniel J Clauw, Mary-Ann Fitzcharles, et al.
Journal of Drugs in Dermatology : JDD|March 4, 2011
Clinical trial safety and mortality analyses in patients receiving etanercept across approved indicationsAlice B Gottlieb, Kenneth Gordon, Edward H Giannini, et al.
Annals of the Rheumatic Diseases|April 22, 2014
Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study)Arthur Kavanaugh, Iain B McInnes, Philip Mease, et al.
Rheumatology and Therapy|June 14, 2024
Correction: Exploring the Effects of Ixekizumab on Pain in Patients with Ankylosing Spondylitis Based on Objective Measures of Inflammation: Post Hoc Analysis from a Large Randomized Clinical TrialKurt de Vlam, Walter P Maksymowych, Gaia Gallo, et al.
Clinical and Experimental Rheumatology|July 5, 2023
Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 studyPhilip Mease, Arathi Setty, Kim Papp, et al.
RMD Open|March 12, 2016
Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain setUmut Kalyoncu, Alexis Ogdie, Willemina Campbell, et al.
The Lancet. Rheumatology|January 30, 2024
Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 studyLaura C Coates, William Tillett, Maria-Antonietta D'Agostino, et al.
Arthritis Research & Therapy|December 28, 2022
Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritisPhilip Mease, Désirée van der Heijde, Bruce Kirkham, et al.
Pageof 18

Showing results (101-110 of 175) with videos related to

Sort By:
Pageof 18
Arthritis and Rheumatism|April 1, 2009
Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled studyArthur Kavanaugh, Iain McInnes, Philip Mease, et al.
Rheumatology and Therapy|April 18, 2024
Exploring the Effects of Ixekizumab on Pain in Patients with Ankylosing Spondylitis Based on Objective Measures of Inflammation: Post Hoc Analysis from a Large Randomized Clinical TrialKurt de Vlam, Walter P Maksymowych, Gaia Gallo, et al.
The Journal of Rheumatology|February 3, 2011
Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for FibromyalgiaFrederick Wolfe, Daniel J Clauw, Mary-Ann Fitzcharles, et al.
Journal of Drugs in Dermatology : JDD|March 4, 2011
Clinical trial safety and mortality analyses in patients receiving etanercept across approved indicationsAlice B Gottlieb, Kenneth Gordon, Edward H Giannini, et al.
Annals of the Rheumatic Diseases|April 22, 2014
Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study)Arthur Kavanaugh, Iain B McInnes, Philip Mease, et al.
Rheumatology and Therapy|June 14, 2024
Correction: Exploring the Effects of Ixekizumab on Pain in Patients with Ankylosing Spondylitis Based on Objective Measures of Inflammation: Post Hoc Analysis from a Large Randomized Clinical TrialKurt de Vlam, Walter P Maksymowych, Gaia Gallo, et al.
Clinical and Experimental Rheumatology|July 5, 2023
Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 studyPhilip Mease, Arathi Setty, Kim Papp, et al.
RMD Open|March 12, 2016
Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain setUmut Kalyoncu, Alexis Ogdie, Willemina Campbell, et al.
The Lancet. Rheumatology|January 30, 2024
Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 studyLaura C Coates, William Tillett, Maria-Antonietta D'Agostino, et al.
Arthritis Research & Therapy|December 28, 2022
Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritisPhilip Mease, Désirée van der Heijde, Bruce Kirkham, et al.
Pageof 18